Coronary Stents Market Report: Drivers, Restraints and Opportunities, Trends and Forecasts to 2023

Published by Infoholic Research on 2nd August 2017 | Ref: 842443 | This Report Is In Stock

$2500 | Single User
$2750 | Site License
$3000 | Enterprise License
$2500 | Single User
$2750 | Site License
$3000 | Enterprise License

Introduction

Indian Market Scenario for Coronary Stent

Cardiovascular diseases account for closely 25% of the deaths in India among the age group of 25 and 70 years. The total number of percutaneous coronary interventions (PCI) is growing gradually at a mid CAGR. In 2016, 495,000 PCI procedures were carried out in India, using 594,000 stents (with an average of 1.2 stents per procedure). Out of these, 80% of the procedures performed used drug-eluting stents (DES), with over 60% of the stents being imported. These MNCs classically go through a supply chain, where the distributors manage the procurement and storage of the stents, and later ship them to the hospitals on requirement. The hospitals add their share of profit to the procured price and bill accordingly. This led to a wide gap between the actual cost of the stent and the selling price to the patient. The average selling price (ASP) of a bare metal stent (BMS) used to be as high as Rs.45,000 (0) and the drug-eluting stents were priced more than Rs.120,000 (,800). This generated a profit between 270% to 1,000%.


Ceiling fixed prices for coronary stents

The notification by National Pharmaceutical Pricing Policy categorizes the stents into bare metal stents (BMS) and drug-eluting stents (DES). Bare metal stents are not to be priced more than Rs.7,260 (0), while drug-eluting stents should be priced below Rs.29,600 (0). This is 40% lesser than the previous prices.

Manufacturer Brand Prices (Rs)

Abbott Laboratories Aborb/ Absorb GT1 31,689

Abbott Laboratories Xience Alpine 31,689

Abbott Laboratories Xience Prime 24,675

Abbott Laboratories Xience Pro 24,675

Abbott Laboratories Xience V 24,675

Abbott Laboratories Xience Xpedition 31,689

Boston Scientific Corporation Promus Element

Boston Scientific Corporation Promus Premier 31,689

Boston Scientific Corporation Synergy 31,689

Meril Life Science Biomime 23,625

Sahajanand Medical Technologies Supraflex 23,289

Biotronik Orsiro 31,689

Vascular Concept Limited Pronova XR 31,689

Does this also include imported stents?

The notification makes no discrepancy between branded or unbranded stents, locally manufactured or imported stents. Any stent sold in the Indian market cannot be charged more than Rs.29,600 (0), though there is the addition of local taxes to these prices. The manufacturers with higher selling price than the cap will have to reduce the prices of their stents, while those selling at lesser prices should maintain their original MRP.

Indian Market Scenario

The Indian coronary stent market is worth currently around 0 million and is anticipated to grow many times in the future due to the growing number of diabetes and hypertension cases. International stent manufacturers, who hold around 60% of the market, are unhappy with the price capping. Hence, they are planning to with withdraw their advanced products from the Indian market and are planning not to bring in the new-generation products in the future. This change may affect the procedural outcomes, especially in complex cases. Thus, India is expected to face more challenges in the future. Abbott requested the removal of its Alpine and Absorb stents from the Indian market, while Medtronic requested to withdraw its Onyx stents. Following them, Boston petitioned for the removal of synergy stents. But their request was rejected by the Indian authorities. This has given a better opportunity for the domestic manufacturers to increase their market share which currently hold less than 40% share.

Regulatory changes for price control

• In July 2016, the coronary stents were included in the National List of Essential Medicines, 2015 (NLEM, 2015) by the Ministry of Health and Family Welfare.

• In December 2016, the coronary stents were given the status of scheduled formulation as in the Drug Price Control Order 2013, by the Department of Pharmaceuticals.


Coronary Stents – competitive scenario

The coronary stents market is segmented into bare metal stents, drug-eluting stents, and bioabsorbable stents. Approximately 90% of all the percutaneous coronary intervention (PCI) surgeries use a coronary stent. Thus, drug-eluting stents hold the major share in the market. The highest growth rate is expected in the bioresorbable stents due to the advantages of the polylactic acid material. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Coronary Stents Market.

The exit of Johnson and Johnson from the coronary stents market has provided an opportunity for many players to strengthen their market share. Abbott Laboratories, Medtronic, and Boston Scientific Corporation are the market leaders in the global coronary stents market in 2016. The top three market players are estimated to hold more than 60% share of the market in 2016. Abbott Laboratories emerged to be the global leader, while Boston Scientific Corporation dominated the market in Brazil and other emerging Latin American countries.

Global coronary stents market growth

The Global Coronary Stents Market is expected to grow at a CAGR of 6.1% during the forecast period 2017–2023. The market is analyzed based on regions and verticals. The market in emerging regions, mergers and acquisitions, and the increase in clinical trials are some factors providing opportunities for the market growth during the forecast period.

Table of Contents

Table of Contents

1 Industry Outlook 8

1.1 Industry Overview 8

1.2 Industry Trends 8

1.3 PEST Analysis 9

2 Report Outline 9

2.1 Report Scope 9

2.2 Report Summary 10

2.3 Research Methodology 11

2.4 Report Assumptions 11

3 Market Snapshot 12

3.1 Total Addressable Market 12

3.2 Segmented Addressable Market 12

3.3 Related Markets 13

4 Market Outlook 15

4.1 Market Definition – Infoholic Research 15

4.2 Causes for Coronary Heart Disease 15

4.3 Market Segmentation 15

4.4 Porter 5(Five) Forces 15

5 Market Characteristics 16

5.1 Evolution 16

5.2 Stents Platforms 17

5.3 Market Dynamics 18

5.4 DRO – Impact Analysis 20

5.5 Key Stakeholders 21

6 Coronary Stents Pipeline 22

6.1 Overview 22

7 Types: Market Size and Analysis 25

7.1 Overview 25

7.2 Bare Metal Stents (BMS) 25

7.3 Drug Eluting Stents 26

7.4 Bio-absorbable Stents 27

8 End-users: Market Size and Analysis 28

8.1 Overview 29

8.2 Hospitals 29

8.3 Ambulatory Surgical Centers (ASCs) 29

8.4 Cardiac Centers 30

9 Regions: Market Size and Analysis 30

9.1 Overview 30

9.2 North America 31

9.3 Europe 33

9.4 Asia Pacific 35

9.5 Rest of the World 37

10 Competitive Landscape 38

10.1 Overview 38

11 Vendors Profile 41

11.1 Abbott Laboratories (Abbott) 41

11.2 Boston Scientific Corp. (Boston) 48

11.3 B. Braun Melsungen AG 54

11.4 Medtronic Plc 59

11.5 MicroPort Scientific Corporation 70

12 Companies to Watch For 76

12.1 Terumo Corp. 77

12.2 Biosensors International Group 79

12.3 BIOTRONIK 80

12.4 Meril Life Science 81

12.5 STENTYS S.A. 82

Annexure 84

Abbreviations 84

Additional Details

Publisher

Infoholic Research

Publisher Information

Reference

842443 |

Number of Pages

85

Report Format

PDF

This report is published by Infoholic Research

Download Free Report Summary PDF

Coronary Stents Market Report: Drivers, Restraints and Opportunities, Trends and Forecasts to 2023 [Updated: 02-08-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.